G6PC1 and metabolic disease: Currently, gene therapies targeting G6PC1 have shown the potential to correct hypoglycemia and prevent other metabolic disorders in GSD-1a animal models16–18 and in a clinical trial (ClinicalTrials.gov Identifier: NCT03517085).